Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Diagnostic services	$ 33,268	$ 12,501	$ 86,877	$ 25,391
Bioscience product sales and services	10,683	10,352	30,423	30,634
Total revenues	43,951	22,853	117,300	56,025
Cost of revenues:
Cost of diagnostic services	23,242	13,836	64,955	30,114
Cost of bioscience product sales and services	3,800	3,711	10,958	10,832
Total cost of revenues	27,042	17,547	75,913	40,946
Gross margin	16,909	5,306	41,387	15,079
Operating expenses:
Selling and marketing	12,400	12,652	39,509	33,639
Research and development	10,415	12,189	37,268	37,103
General and administrative	14,131	10,126	40,349	27,425
Restructuring Charges	6,018	0	6,018	0
Total operating expenses	42,964	34,967	123,144	98,167
Loss from operations	(26,055)	(29,661)	(81,757)	(83,088)
Interest expense, net	(2,106)	(600)	(6,396)	(1,146)
Other income (expense), net	111	44	(134)	(1)
Loss before income taxes	(28,050)	(30,217)	(88,287)	(84,235)
Income tax expense	(98)	(20)	(244)	(42)
Net loss	(28,148)	(30,237)	(88,531)	(84,277)
Net loss per common share, basic and diluted (in USD per share)	$ (0.24)	$ (0.26)	$ (0.77)	$ (0.74)
Weighted average number of shares outstanding, basic and diluted (in shares)	115,592	114,712	115,255	113,263
Statements of Comprehensive Loss
Net loss	(28,148)	(30,237)	(88,531)	(84,277)
Other comprehensive income (loss):
Unrealized gain on available-for-sale securities	41	8	73	19
Foreign currency translation adjustment	205	147	88	(22)
Total other comprehensive income (loss)	246	155	161	(3)
Comprehensive loss	$ (27,902)	$ (30,082)	$ (88,370)	$ (84,280)